Keyword: Bristol-Myers Squibb
Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.
Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go through.
Just a week after Roche’s Tecentriq became the first FDA-approved I-O agent in breast cancer, the drug has clinched another first-in-class nod.
Eliquis has new data showing the next-gen anticoagulant is safer than warfarin for a tough-to-treat group of atrial fibrillation patients.
Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict
CMS has rolled out data to show which drugs dominated the most federal spending in 2017 and how their pricing changed from prior years
Much of the doubt surrounding BMS' $74 billion Celgene buy centers on Revlimid's patent life. But the companies just scored a win in that department.
Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
What's Bristol-Myers' Plan B if its Celgene deal falls through? The company won't say whether it has one, much less what it might be.
BMS responded to Starboard Value's attempt to scuttle its $74 billion acquisition of Celgene with 46 pages laying out its reasoning for the deal.